Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06383338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

Study acronym: PEGASUS
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2026 → Nov 2026
See other at-risk trials from Murdoch Childrens Research Institute

Record History

  1. Primary and study completion pushed from Jul 2026 to Nov 2026v7
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2025 to Jul 22, 2025 · Site details revisedv6 Show 2 more changesShow less
    • Start date changed from estimate of Jul 2025 to Jul 22, 2025
    • Site details revised
  3. Start date: Mar 2025 to Jul 2025 Primary and study completion dates: Mar 2026 to Jul 2026v5 Show 1 more changeShow less
    • Primary and study completion dates: Mar 2026 to Jul 2026
  4. Re-verified, no change to tracked fieldsv4
  5. Primary completion date: May 2025 to Mar 2026 Start date: Jul 2024 to Mar 2025 · Completion date: May 2026 to Mar 2026v3 Show 2 more changesShow less
    • Start date: Jul 2024 to Mar 2025
    • Completion date: May 2026 to Mar 2026
  6. Start date: May 2024 to Jul 2024v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
Trial Details
NCT Number NCT06383338
Lead Sponsor Murdoch Childrens Research Institute
Conditions Hodgkin Lymphoma, Non Hodgkin Lymphoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov